Sulzer Inter Op
This article was originally published in The Gray Sheet
Executive Summary
Financial impact of voluntary December 5 recall of the acetabular shell hip implant will be larger than initially anticipated as revision surgeries exceed 1,700 to date, the firm reports May 21. Insurance will be insufficient to meet the firm's commitment to "fair" reimbursement of related expenses, contrary to earlier projections, Sulzer says. The firm notes weekly surgeries are declining, however. The recall stems from aseptic loosening due to residue left on the shell's surface from the machining process (1"The Gray Sheet" Jan. 22, 2001, p. 14)